Grufity logoGrufity logo

Biogen Inc Stock Research

BIIB

270.03USD+4.86(+1.83%)Market Closed

Market Summary

USD270.03+4.86
Market Closed
1.83%

BIIB Alerts

BIIB Stock Price

BIIB RSI Chart

BIIB Valuation

Market Cap

39.0B

Price/Earnings (Trailing)

12.8

Price/Sales (Trailing)

3.83

EV/EBITDA

9.61

Price/Free Cashflow

34.08

BIIB Price/Sales (Trailing)

BIIB Profitability

EBT Margin

35.31%

Return on Equity

22.74%

Return on Assets

12.41%

Free Cashflow Yield

2.93%

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

10.2B

Revenue Y/Y

-6.94%

Revenue Q/Q

1.42%

BIIB Earnings

Earnings (TTM)

3.0B

Earnings Y/Y

49.48%

Earnings Q/Q

-51.49%

Price Action

52 Week Range

187.16311.88
(Low)(High)

Last 7 days

1.8%

Last 30 days

-0.9%

Last 90 days

-3.3%

Trailing 12 Months

26.8%

BIIB Financial Health

Current Ratio

2.99

Debt/Equity

0.47

Debt/Cashflow

0.22

BIIB Investor Care

Buy Backs (1Y)

2.43%

Diluted EPS (TTM)

20.87

Peers (Alternatives to Biogen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
127.1B
26.3B
0.79% 2.78%
19.4
4.83
1.32% 11.18%
99.8B
27.3B
-4.19% 39.66%
21.72
3.66
-0.09% -26.23%
58.1B
19.3B
-4.61% -16.03%
6.95
3.02
4.29% -31.47%
39.0B
10.2B
-0.92% 26.77%
12.8
3.83
-7.36% 95.80%
MID-CAP
9.4B
1.5B
-5.59% 3.19%
60.62
6.29
31.34% 72.43%
3.1B
108.5M
-21.66% -32.82%
-9.55
28.71
122.90% -12.19%
2.2B
107.9M
21.83% 38.60%
-4.63
20.79
54.84% 17.36%
2.2B
60.9M
-25.55% -48.21%
-7.49
35.56
17.51% 22.00%
SMALL-CAP
1.3B
112.0M
-7.70% -49.25%
-4.81
11.47
-70.76% -603.77%
1.1B
7.0M
-17.00% 22.02%
-7.14
159.78
131.81% -45.39%
524.4M
96.3M
-14.58% -86.07%
-1.86
5.45
72.44% -32.79%
519.7M
2.0B
-33.63% -92.58%
-0.79
0.26
72.89% 62.27%
276.9M
111.3M
-42.96% -71.96%
-1.44
2.49
0.54% -7.86%
101.6M
107.0K
-17.23% -85.52%
-0.94
949.93
-88.00% -52.91%
26.0M
-
40.00% -84.44%
-0.32
3.21
0.51% -185.61%

Financials for Biogen

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-1.8%10,17310,36310,63410,82010,982
  S&GA Expenses-6.1%2,4042,5592,6502,7142,674
Costs and Expenses-1.9%6,5826,7078,0578,9319,237
EBITDA4.1%4,3574,1843,1232,407-
EBITDA Margin6.1%0.43*0.40*0.29*0.22*-
Earnings Before Taxes5.9%3,5923,3932,3131,6261,745
EBT Margin7.8%0.35*0.33*0.22*0.15*-
Interest Expenses-4.5%247258265255254
Net Income6.4%3,0472,8652,0591,4501,556
Net Income Margin8.3%0.30*0.28*0.19*0.13*-
Free Cahsflow-47.8%1,1442,1922,3542,809-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-1.2%24,55424,85425,08123,61423,877
  Current Assets0.3%9,7919,7669,7417,9167,857
    Cash Equivalents-7.0%3,4193,6762,6471,7492,261
  Inventory-2.2%1,3441,3751,2941,2151,352
  Net PPE1.0%3,2993,2663,3553,3733,416
  Goodwill0.1%5,7495,7415,7505,7585,761
Liabilities-7.6%11,16612,08713,21812,39412,918
  Current Liabilities-16.6%3,2733,9265,0183,9474,298
  Long Term Debt0.0%6,2816,2796,2776,2766,274
Shareholder's Equity4.9%13,39812,77611,86311,22110,896
  Retained Earnings3.5%16,46715,91614,96014,21613,912
  Additional Paid-In CapitalInfinity%73.00--11968.00
Accumulated Depreciation-2,007----
Shares Outstanding-1.0%144146147--
Minority Interest-9.2%-9.50-8.70-9.10-21.6064.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-42.3%1,3842,3982,5423,0333,640
  Share Based Compensation9311.1%2543.0011.0013.00239
Cashflow From Investing-1.8%1,5771,605-300-1,147-563
Cashflow From Financing-1.0%-1,747-1,730-1,224-1,317-2,086
  Buy Backs0%7507501,2501,2001,800

Risks for BIIB

What is the probability of a big loss on BIIB?

87.3%


Probability that Biogen stock will be more than 20% underwater in next one year

55.8%


Probability that Biogen stock will be more than 30% underwater in next one year.

15%


Probability that Biogen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BIIB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Biogen was unfortunately bought at previous high price.

Drawdowns

Returns for BIIB

Cumulative Returns on BIIB

5.2%


10-Year Cumulative Returns

2.0%


7-Year Cumulative Returns

0.8%


5-Year Cumulative Returns

-0.7%


3-Year Cumulative Returns

What are the long-term rolling returns for BIIB?

FIve years rolling returns for Biogen.

Annualized Returns

Which funds bought or sold BIIB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
14.22
208,339
1,343,340
0.04%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-4.7
-505,418
43,161,600
0.05%
2023-03-06
Rockefeller Capital Management L.P.
added
4.87
144,000
1,789,000
0.01%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
reduced
-2.03
4,967
279,967
0.02%
2023-03-03
TIAA, FSB
reduced
-14.89
-148,012
1,115,990
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
new
-
7,200
7,200
-%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
1,961,700
1,961,700
0.02%
2023-03-01
Regal Investment Advisors LLC
reduced
-2.18
6,318
435,318
0.04%
2023-02-28
Voya Investment Management LLC
added
2.58
1,972,790
32,853,800
0.05%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
385
1,385
-%

1–10 of 45

Latest Funds Activity

Are funds buying BIIB calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BIIB
No. of Funds

Biogen News

Best Stocks

Gofen & Glossberg LLC IL acquires new shares of Biogen Inc ....

Best Stocks,
15 hours ago

Investing News Network

The Motley Fool

The Motley Fool

Schedule 13G FIlings of Biogen

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.32%
11,976,623
SC 13G/A
Feb 09, 2023
primecap management co/ca/
10.9%
15,700,576
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
14,260,137
SC 13G/A
Mar 07, 2022
blackrock inc.
9.4%
13,736,954
SC 13G/A
Feb 10, 2022
primecap management co/ca/
10.73%
15,757,405
SC 13G/A
Feb 09, 2022
vanguard group inc
7.85%
11,537,299
SC 13G/A
Feb 08, 2022
blackrock inc.
9.4%
13,736,954
SC 13G
Feb 12, 2021
primecap management co/ca/
10.28%
15,822,066
SC 13G/A
Feb 10, 2021
vanguard group inc
7.73%
11,896,510
SC 13G/A
Jan 29, 2021
blackrock inc.
8.7%
13,419,601
SC 13G/A

BIIB Fair Value

Biogen fair value in different scenarios

The table shows the Fair Value estimates for Biogen for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

152.60

-43.49%

191.69

-29.01%

289.90

7.36%

365.74

35.44%

420.23

55.62%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Biogen Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Biogen

View All Filings
Date Filed Form Type Document
Mar 09, 2023
8-K
Current Report
Mar 06, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 15, 2023
10-K
Annual Report

Latest Insider Trading transactions for BIIB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-02
Singhal Priya
sold (taxes)
-184,631
268
-687
head of development
2023-03-02
Singhal Priya
acquired
-
-
297
head of development
2023-02-17
Singhal Priya
sold (taxes)
-42,035
278
-151
head of development
2023-02-17
Kramer Robin
acquired
-
-
512
chief accounting officer
2023-02-17
ALEXANDER SUSAN H
sold (taxes)
-258,615
278
-929
evp chief legal off & corp sec
2023-02-17
Singhal Priya
acquired
-
-
460
head of development
2023-02-17
Gregory Ginger
sold (taxes)
-241,355
278
-867
evp, human resources
2023-02-17
Izzar Rachid
acquired
-
-
767
head of global product strat.
2023-02-17
MCDONNELL MICHAEL R
acquired
-
-
2,561
evp, chief financial officer
2023-02-17
MCDONNELL MICHAEL R
sold (taxes)
-364,678
278
-1,310
evp, chief financial officer

1–10 of 50

Michel Vounatsos
9610
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Income Statement

2022-12-31
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues$ 10,173.4$ 10,981.7$ 13,444.6
Cost and expense:   
Cost of sales, excluding amortization and impairment of acquired intangible assets2,278.32,109.71,805.2
Research and development2,231.12,501.23,990.9
Selling, general and administrative2,403.62,674.32,504.5
Amortization and impairment of acquired intangible assets365.9881.3464.8
Collaboration profit (loss) sharing(7.4)7.2232.9
(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations0.00.0(92.5)
(Gain) loss on fair value remeasurement of contingent consideration(209.1)(50.7)(86.3)
Acquired in-process research and development0.018.075.0
Restructuring charges131.10.00.0
Gain on sale of building(503.7)0.00.0
Other (income) expense, net(108.2)1,095.5(497.4)
Total cost and expense6,581.69,236.58,397.1
Income before income tax expense and equity in loss of investee, net of tax3,591.81,745.25,047.5
Income tax (benefit) expense632.852.5992.3
Equity in (income) loss of investee, net of tax(2.6)(34.9)(5.3)
Net income2,961.61,727.64,060.5
Net income (loss) attributable to noncontrolling interests, net of tax(85.3)171.559.9
Net income attributable to Biogen Inc.$ 3,046.9$ 1,556.1$ 4,000.6
Net income per share:   
Basic earnings per share attributable to Biogen Inc. (in dollars per share)$ 20.96$ 10.44$ 24.86
Diluted earnings per share attributable to Biogen Inc. (in dollars per share)$ 20.87$ 10.40$ 24.80
Weighted-average shares used in calculating:   
Weighted average number of common shares outstanding (in shares)145,300149,100160,900
Diluted earnings per share attributable to Biogen Inc. (in shares)146,000149,600161,300
Product, net   
Revenues$ 7,987.8$ 8,846.9$ 10,692.2
Revenue from anti-CD20 therapeutic programs   
Revenues1,700.51,658.51,977.8
Other   
Revenues$ 485.1$ 476.3$ 774.6

BIIB Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 3,419.3$ 2,261.4
Marketable securities1,473.51,541.1
Accounts receivable, net1,705.01,549.4
Due from anti-CD20 therapeutic programs431.4412.3
Inventory1,344.41,351.5
Other current assets1,417.6740.8
Total current assets9,791.27,856.5
Marketable securities705.7892.0
Property, plant and equipment, net3,298.63,416.4
Operating lease assets403.9375.4
Intangible assets, net1,850.12,221.3
Goodwill5,749.05,761.1
Deferred tax asset1,226.41,415.1
Investments and other assets1,529.21,939.5
Total assets24,554.123,877.3
Current liabilities:  
Current portion of notes payable0.0999.1
Taxes payable259.9174.7
Accounts payable491.5589.2
Accrued expense and other2,521.42,535.2
Total current liabilities3,272.84,298.2
Notes payable6,281.06,274.0
Deferred tax liability334.7694.5
Long-term operating lease liabilities333.0330.4
Other long-term liabilities944.21,320.5
Total liabilities11,165.712,917.6
Commitments, contingencies and guarantees (Notes 22 and 23)
Biogen Inc. shareholders’ equity  
Preferred stock, par value $0.001 per share0.00.0
Common stock, par value $0.0005 per share0.10.1
Additional paid-in capital73.368.2
Accumulated other comprehensive loss(164.9)(106.7)
Retained earnings16,466.513,911.7
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively(2,977.1)(2,977.1)
Total Biogen Inc. shareholders’ equity13,397.910,896.2
Noncontrolling interests(9.5)63.5
Total equity13,388.410,959.7
Total liabilities and equity$ 24,554.1$ 23,877.3